NEW YORK (GenomeWeb News) – Predictive Biosciences and Affinity Life Sciences today said they are collaborating to develop biomarker assays for use in clinical studies.
Financial and other terms of the deal were not disclosed.
In a statement, Predictive Bio, based in Lexington, Ky., said the collaboration provides it with access to Affinity's expertise in biomarker immunoassay development. It added that with Affinity's support it will expand its cancer diagnostic menu.
Predictive develops molecular diagnostic cancer assays and provides anatomic pathology laboratory solutions. Affinity is a contract research organization based in Milford, NH, specializing in biomarker and immunochemistry assay development for research use or under cGMP conditions.